Last update Feb. 11, 2020
Very High Risk
A selective and reversible inhibitor of Janus kinases 1 and 2.
It is used alone or associated with methotrexate in moderate to severe rheumatoid arthritis, in psoriatic arthritis and ulcerative colitis.
Oral administration twice a day.
Since the last update we have not found published data on its excretion in breastmilk.
Its pharmacokinetic data makes it difficult to accurately predict its possible excretion in breastmilk, because although its high volume of distribution would hinder it, its low molecular weight and low fixation to plasma proteins would facilitate it.
Its frequent side effects are infections that can be serious, anemia and hypertension
Until there is more published data on this drug in relation to breastfeeding, safer known alternatives may be preferable (Mahadevan 2019, Louthrenoo 2017, Götestam 2016), especially during the neonatal period and in cases of prematurity.
Suggestions made at e-lactancia are done by APILAM team of health professionals, and are based on updated scientific publications. It is not intended to replace the relationship you have with your doctor but to compound it. The pharmaceutical industry contraindicates breastfeeding, mistakenly and without scientific reasons, in most of the drug data sheets.
Your contribution is essential for this service to continue to exist. We need the generosity of people like you who believe in the benefits of breastfeeding.
Thank you for helping to protect and promote breastfeeding.
e-lactancia is a resource recommended by Academy of Breastfeeding Medicine - 2012 of United States of America
Would you like to recommend the use of e-lactancia? Write to us at corporate mail of APILAM